The 63,632 drug overdose deaths in the United States in 2016 represented a 21.4% increase from 2015; two thirds of these deaths involved an opioid (1) . From 2015 to 2016, drug overdose deaths increased in all drug categories examined; the largest increase occurred among deaths involving synthetic opioids other than methadone (synthetic opioids), which includes illicitly manufactured fentanyl (IMF) (1) . Since 2013, driven largely by IMF, including fentanyl analogs (2) (3) (4) , the current wave of the opioid overdose epidemic has been marked by increases in deaths involving synthetic opioids. IMF has contributed to increases in overdose deaths, with geographic differences reported (1). CDC examined state-level changes in death rates involving all drug overdoses in 50 states and the District of Columbia (DC) and those involving synthetic opioids in 20 states, during 2013-2017. In addition, changes in death rates from 2016 to 2017 involving all opioids and opioid subcategories,* were examined by demographics, county urbanization levels, and by 34 states and DC. Among 70,237 drug overdose deaths in 2017, 47,600 (67.8%) involved an opioid. † From 2013 to 2017, drug overdose death rates increased in 35 of 50 states and DC, and significant increases in death rates involving synthetic opioids occurred in 15 of 20 states, likely driven by IMF (2, 3) . From 2016 to 2017, overdose deaths involving all opioids and synthetic opioids increased, but deaths involving prescription opioids and heroin remained stable. The opioid overdose epidemic continues to worsen and evolve because of the continuing increase in deaths involving synthetic opioids. Provisional data from 2018 indicate potential improvements in some drug overdose indicators; § however, analysis of final data from 2018 is necessary for confirmation. More timely and comprehensive surveillance data are essential to inform efforts to prevent and respond to opioid overdoses; intensified prevention and response measures are urgently needed to curb deaths involving prescription and illicit opioids, specifically IMF.
Drug overdose deaths were identified in the National Vital Statistics System multiple cause-of-death mortality files, ¶ with death certificate data coded using the International Classification of * Natural opioids include morphine and codeine, and semisynthetic opioids include drugs such as oxycodone, hydrocodone, hydromorphone, and oxymorphone. Methadone is a synthetic opioid. Prescription opioids include methadone, natural, and semisynthetic opioids. Synthetic opioids, other than methadone, include drugs such as tramadol and fentanyl. Heroin is an illicit opioid synthesized from morphine that can be a white or brown powder or a black, sticky substance. † https://www.cdc.gov/nchs/products/databriefs/db329.htm. § https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. ¶ https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm.
Diseases, Tenth Revision (ICD-10) codes X40-44 (unintentional), X60-64 (suicide), X85 (homicide), or Y10-Y14 (undetermined intent). Among deaths with drug overdose as the underlying cause, the type of drug or drug category is indicated by the following ICD-10 multiple cause-of-death codes: opioids (T40.0, T40.1, T40.2, T40.3, T40.4, or T40.6)**; natural/semisynthetic opioids (T40.2); methadone (T40.3); heroin (T40.1); synthetic opioids other than methadone (T40.4); cocaine (T40.5); and psychostimulants with abuse potential (T43.6). † † Some deaths involved more than one type of drug, and these were included in rates for each drug category; thus, categories are not mutually exclusive. § § Annual percent change with statistically significant trends in ageadjusted drug overdose death rates ¶ ¶ for all 50 states and DC from 2013 to 2017 and in age-adjusted death rates involving synthetic opioids for 20 states that met drug specificity criteria*** were analyzed using Joinpoint regression. † † † Age-adjusted overdose death rates were examined from 2016 to 2017 for all opioids, prescription opioids (5), heroin, and synthetic opioids. Death rates were stratified by age, sex, racial/ethnic group, urbanization level, § § § and state. State-level analyses included DC and 34 states with adequate drug ** T40.0 (opium) and T40.6 (other and unspecified narcotics).
† † Psychostimulants with abuse potential include drugs such as methamphetamine and 3,4-methylenedioxy-methamphetamine (MDMA). § § For example, a death involving both a synthetic opioid other than methadone and heroin would be included in both the synthetic opioid other than methadone and heroin death rates. ¶ ¶ Age-adjusted death rates were calculated by applying age-specific death rates to the 2000 U.S. Census standard population age distribution https:// www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_04.pdf. *** State-level analyses for synthetic opioid-involved overdose deaths, comparing death rates from 2013 to 2017, included 20 states that met the following criteria: 1) >80% of drug overdose death certificates named at least one specific drug in 2013-2017; 2) Synthetic opioids were involved in 59.8% of all opioid-involved overdose deaths; the rate increased by 45.2% from 2016 to 2017 (Table 2) . From 2013 through 2017, overdose death rates increased significantly in 35 states and DC; 15 of 20 states that met drug specificity criteria had significant increases in overdose death rates involving synthetic opioids (Figure) . From 2016 to 2017, death rates involving cocaine and psychostimulants increased 34.4% (from 3.2 to 4.3 per 100,000) and 33.3% (from 2.4 to 3.2 per 100,000), respectively, likely contributing to increases in drug overdose deaths; however, rates remained stable for deaths involving prescription opioids (5.2 per 100,000) ( Table 1 ) and heroin (4.9) ( Table 2) . From 2016 to 2017, opioid-involved overdose deaths increased among males and females and among persons aged ≥25 years, non-Hispanic whites (whites), non-Hispanic blacks (blacks), and Hispanics ( Table 1 ). The largest relative change occurred among blacks (25.2%), and the largest absolute rate increase was among males aged 25-44 years (an increase of 4.6 per 100,000). The largest relative change among age groups was for persons aged ≥65 years (17.2%). Counties in medium metro -10) . Drug overdose deaths are identified using underlying cause-of-death codes X40-X44, X60-X64, X85, and Y10-Y14. Rates are age-adjusted using the direct method and the 2000 U.S. standard population, except for age-specific crude rates. All rates are per 100,000 population. † Drug overdose deaths, as defined, that have opium (T40.0), heroin (T40.1), natural and semisynthetic opioids (T40.2), methadone (T40.3), synthetic opioids other than methadone (T40.4), or other and unspecified narcotics (T40.6) as a contributing cause. § Drug overdose deaths, as defined, that have natural and semisynthetic opioids (T40.2) or methadone (T40.3) as a contributing cause. ¶ Categories of deaths are not exclusive because deaths might involve more than one drug. Summing of categories will result in more than the total number of deaths in a year. ** Data for Hispanic origin should be interpreted with caution; studies comparing Hispanic origin on death certificates and on census surveys have shown inconsistent reporting on Hispanic ethnicity. Potential race misclassification might lead to underestimates for certain categories, primarily American Indian/Alaska Native non-Hispanic and Asian/Pacific Islander non-Hispanic decedents. https://www.cdc.gov/nchs/data/series/sr_02/sr02_172.pdf. † † By 2013 urbanization classification (https://www.cdc.gov/nchs/data_access/urban_rural.htm). § § Analyses were limited to states meeting the following criteria. For states with very good to excellent reporting, ≥90% of drug overdose deaths mention at least one specific drug in 2016, with the change in drug overdose deaths mentioning at least one specific drug differing by <10 percentage points from 2016 to 2017. States with good reporting had 80% to <90% of drug overdose deaths mention at least one specific drug in 2016, with the change in the percentage of drug overdose deaths mentioning at least one specific drug differing by <10 percentage points from 2016 to 2017. States included also were required to have stable rate estimates, based on ≥20 deaths, in at least two drug categories (i.e., opioids, prescription opioids, synthetic opioids other than methadone, and heroin). ¶ ¶ Absolute rate change is the difference between 2016 and 2017 rates. Percent change is the absolute rate change divided by the 2016 rate, multiplied by 100.
Nonoverlapping confidence intervals based on the gamma method were used if the number of deaths was <100 in 2016 or 2017, and z-tests were used if the number of deaths was ≥100 in both 2016 and 2017. *** Statistically significant (P-value <0.05). -10) . Drug overdose deaths are identified using underlying cause-of-death codes X40-X44, X60-X64, X85, and Y10-Y14. Rates are age-adjusted using the direct method and the 2000 U.S. standard population, except for age-specific crude rates. All rates are per 100,000 population. † Drug overdose deaths, as defined, that have heroin (T40.1) as a contributing cause. § Drug overdose deaths, as defined, that have semisynthetic opioids other than methadone (T40.4) as a contributing cause. ¶ Categories of deaths are not exclusive as deaths might involve more than one drug. Summing of categories will result in more than the total number of deaths in a year. ** Data on Hispanic origin should be interpreted with caution; studies comparing Hispanic origin on death certificates and on census surveys have shown inconsistent reporting on Hispanic ethnicity. Potential race misclassification might lead to underestimates for certain categories, primarily American Indian/Alaska Native non-Hispanic and Asian/Pacific Islander non-Hispanic decedents. https://www.cdc.gov/nchs/data/series/sr_02/sr02_172.pdf. † † By 2013 urbanization classification (https://www.cdc.gov/nchs/data_access/urban_rural.htm). § § Analyses were limited to states meeting the following criteria. For states with very good to excellent reporting, ≥90% of drug overdose deaths mention at least one specific drug in 2016, with the change in drug overdose deaths mentioning at least one specific drug differing by <10 percentage points from 2016 to 2017. States with good reporting had 80% to <90% of drug overdose deaths mention at least one specific drug in 2016, with the change in the percentage of drug overdose deaths mentioning at least one specific drug differing by <10 percentage points from 2016 to 2017. States included also were required to have stable rate estimates, based on ≥20 deaths, in at least two drug categories (i.e., opioids, prescription opioids, synthetic opioids other than methadone, and heroin). ¶ ¶ Absolute rate change is the difference between 2016 and 2017 rates. Percent change is the absolute rate change divided by the 2016 rate, multiplied by 100.
Nonoverlapping confidence intervals based on the gamma method were used if the number of deaths was <100 in 2016 or 2017, and z-tests were used if the number of deaths was ≥100 in both 2016 and 2017. Note that the method of comparing confidence intervals is a conservative method for statistical significance; caution should be observed when interpreting a nonsignificant difference when the lower and upper limits being compared overlap only slightly. Confidence intervals of 2016 and 2017 rates of synthetic opioid-involved deaths in Iowa overlapped only slightly: (1.40, 2.39), (2.36, 3.59 ). *** Statistically significant (P-value <0.05). † † † Cells with ≤9 deaths are not reported. Rates based on <20 deaths are not considered reliable and are not reported. (primarily IMF) were involved in 23.7% of deaths involving prescription opioids, 37.4% involving heroin, and 40.3% involving cocaine (9) . In addition, death rates are increasing across multiple demographic groups. For example, although death rates involving opioids remained highest among whites, relatively large increases across several drug categories were observed among blacks. The findings in this report are subject to at least five limitations. First, at autopsy, substances tested for vary by time and jurisdiction, and improvements in toxicologic testing might account for some reported increases. Second, the specific types of drugs involved were not included on 15% of drug overdose death certificates in 2016 and 12% in 2017, and the percentage of death certificates with at least one drug specified ranged among states from 54.7%-99.3% in 2017, limiting rate comparisons between states. Third, because heroin and morphine are metabolized similarly (10) , some heroin deaths might have been misclassified as morphine deaths, resulting in underreporting of heroin deaths. Fourth, potential race misclassification might have led to underestimates for certain categories, primarily for American Indian/Alaska Natives and Asian/Pacific Islanders.***** Finally, most state-specific analyses were restricted to DC and a subset of states with adequate drug specificity, limiting generalizability.
FIGURE. Age
Through 2017, the drug overdose epidemic continues to worsen and evolve, and the involvement of many types of drugs (e.g., opioids, cocaine, and methamphetamine) underscores the urgency to obtain more timely and local data to inform public health and public safety action. Although prescription opioidand heroin-involved death rates were stable from 2016 to 2017, they remained high. Some preliminary indicators in 2018 point to possible improvements based on provisional data; † † † † † however, confirmation will depend on results of pending medical investigations and analysis of final data. Overall, deaths involving synthetic opioids continue to drive increases in overdose deaths. CDC funds 32 states and DC to collect more timely and comprehensive drug overdose data, including improved toxicologic testing in opioid-involved fatal overdoses. § § § § § CDC is funding prevention activities in 42 states and DC. ¶ ¶ ¶ ¶ ¶ CDC also is leveraging emergency funding to support 49 states, DC, and four territories to broaden their surveillance and response capabilities and enable comprehensive communitylevel responses with implementation of novel, evidence-based interventions.****** Continued efforts to ensure safe prescribing practices by following the CDC Guideline for Prescribing Opioids for Chronic Pain † † † † † † are enhanced by access to nonopioid and nonpharmacologic treatments for pain. Other important activities include increasing naloxone availability, expanding access to medication-assisted treatment, enhancing public health and public safety partnerships, and maximizing the ability of health systems to link persons to treatment and harm-reduction services. ***** https://www.cdc.gov/nchs/data/series/sr_02/sr02_172.pdf. † † † † † https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. § § § § § https://www.cdc.gov/drugoverdose/foa/state-opioid-mm.html. ¶ ¶ ¶ ¶ ¶ https://www.cdc.gov/drugoverdose/states/state_prevention.html. https://www. cdc.gov/drugoverdose/foa/ddpi.html. ****** https://www.cdc.gov/cpr/readiness/funding-opioid.htm. † † † † † † https://www.cdc.gov/drugoverdose/prescribing/guideline.html.
Summary
What is already known about this topic?
The U.S. opioid overdose epidemic continues to evolve. In 2016, 66.4% of the 63,632 drug overdose deaths involved an opioid.
What is added by this report?
In 2017, among 70,237 drug overdose deaths, 47,600 (67.8%) involved opioids, with increases across age groups, racial/ethnic groups, county urbanization levels, and in multiple states. From 2013 to 2017, synthetic opioids contributed to increases in drug overdose death rates in several states. From 2016 to 2017, synthetic opioid-involved overdose death rates increased 45.2%.
What are the implications for public health practice?
Continued federal, state, and local surveillance efforts to inform evidence-based prevention, response, and treatment strategies and to strengthen public health and public safety partnerships are urgently needed.
